Literature DB >> 1895324

Rat model of chronic lung infections caused by non-typable Haemophilus influenzae.

I Maciver1, S H Silverman, M R Brown, T O'Reilly.   

Abstract

Patients with chronic obstructive pulmonary disease (COPD) often have chronic or recurrent pulmonary infections with non-typable Haemophilus influenzae. A model of these infections exploited agar bead vehicles to protect the inoculum from rapid clearance, and a chronic lung infection of at least 42 days duration was established in rats. This infection induced increases in serum IgG titres to outer-membrane (OM) and lipo-oligosaccharide (LOS) antigens; immunoblotting demonstrated that this humoral response was directed partly against the outer-membrane proteins (OMPs). Lung lavage fluid also contained an increased titre of IgG antibodies to OM and LOS 42 days after infection. Antibodies produced during infection with one strain of H. influenzae cross-reacted with OMPs from another, non-typable H. influenzae strain. Despite their encasement in agar beads, pulmonary H. influenzae remained susceptible to amoxycillin. This model of chronic pulmonary infections due to non-typable H. influenzae appears to resemble the situation in COPD patients and may be useful for experimental therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895324     DOI: 10.1099/00222615-35-3-139

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  2 in total

1.  Development of experimental respiratory infections in neutropenic rats with either penicillin-resistant Streptococcus pneumoniae or beta-lactamase-producing Haemophilus influenzae.

Authors:  G M Smith; K H Abbott
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 2.  Rodent models of cardiopulmonary disease: their potential applicability in studies of air pollutant susceptibility.

Authors:  U P Kodavanti; D L Costa; P A Bromberg
Journal:  Environ Health Perspect       Date:  1998-02       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.